MK-5684-003: A PHASE 3 STUDY OF CYP11A1 INHIBITOR OPEVESOSTAT VERSUS NEXT-GENERATION HORMONAL AGENT (NHA) SWITCH IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER NHA AND TAXANE-BASED CHEMOTHERAPY

DOI: 10.1016/j.urolonc.2024.12.066 Publication Date: 2025-02-27T16:03:02Z